

Pharmacology of Antibiotics: Protein Synthesis Inhibitors

Leslie Goldstein, Pharm.D.

Associate Professor

Department of Clinical Specialties
Pharmacology Division

lgolds01@nyit.edu



NEW YORK INSTITUTE OF TECHNOLOGY

College of Osteopathic
Medicine

Do.
Make.
Heal.
Innovate.
Reinvent the Future.

I am available to groups and individuals for pharmacology help and discussions by appointment.

lgolds01@nyit.edu

After completing the preparation materials, students should be able to:

1. Correlate the pharmacokinetic properties of each of the classes of protein synthesis inhibitors with their clinical relevance for optimizing patient care.
2. Identify and differentiate the mechanisms of action, resistance, and cross-resistance of each of the protein synthesis inhibitors.
3. Construct a chart or mind map of the spectrums of activity for each of the protein synthesis inhibitors correlated with their therapeutic applications.
4. Apply your knowledge of the mechanisms of drug-drug, drug-disease, and drug-food interactions, potential adverse drug reactions, and contraindications of each of the protein synthesis inhibitors when given a case vignette.

Mechanisms
Mechanisms
Mechanisms

Chunk
concepts
together

APPLY
your
knowledge

Preparation Materials (links are in the CPG and on the next slide)

Required

- ScholarRx Bricks | Practice Questions and Clinical Vignettes

Highly relevant optional materials:

- Video lecture | Dr. Goldstein's Word handout | Guided reading questions
- Textbooks and Examination Review Books (please see next slide)

SUGGESTIONS:

- ***Use the resources that work best for you.***
- ***You do not need to study all of them. (ScholarRx Bricks & Practice Questions are required.)***
- ***Work through the GUIDED READING QUESTIONS with pen/pencil and paper.***

Try answering them in your OWN WORDS first without looking at the readings, and then again after reviewing.

- ***Practice questions (not graded): Simple Recall and Case Vignettes***

Links to Materials

Name of Discipline/ Organ System: General Microbiology > Antimicrobial Agents

Title of Brick(s): Antibacterial Drugs > Protein Synthesis Inhibitors

Link: <https://exchange.scholarrx.com/brick/protein-synthesis-inhibitors>

Access Medicine Katzung's Basic & Clinical Pharmacology, 16e, 2024; Chapter 44: Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Oxazolidones, & Pleuromutilins

<https://accessmedicine.mhmedical.com.nyit.idm.oclc.org/content.aspx?bookid=3382§ionid=281754666>


Access Medicine Katzung's Basic & Clinical Pharmacology: Examination & Board Review, 13e, 2024; Chapter 44: Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, & Oxazolidones

<https://accessmedicine.mhmedical.com.nyit.idm.oclc.org/content.aspx?bookid=3461§ionid=285597887>

LWW Health Libraries Medical Education: Lippincott's Illustrated Reviews, Pharmacology, 8e, 2023; Chapter 30: Protein Synthesis Inhibitors

<https://meded-lwwhealthlibrary-com.idm.oclc.org/content.aspx?sectionid=253328689&bookid=3222>

bacterial ribosome



Key points: What you need to know and understand

- Several antibiotics produce antimicrobial effects by targeting bacterial ribosomes and inhibiting bacterial protein synthesis.
- Bacterial ribosomes are composed of 30S and 50S ribosomal subunits. They differ structurally from mammalian cytoplasmic ribosomes, which are composed of 40S and 60S subunits. However, mitochondrial ribosomes are similar to bacterial ribosomes in structure and size.
- In general, the antibacterial protein synthesis inhibitors are selective for the bacterial ribosome, minimizing potential adverse effects that would occur with inhibition of host protein synthesis.
- Protein synthesis inhibitors are bacteriostatic for the most part. Some have bactericidal activity against some bacteria. Aminoglycosides are bactericidal.
- Some protein synthesis inhibitors, notably chloramphenicol and linezolid and possibly others, can cause dose-dependent toxic effects due to inhibition of mitochondrial protein synthesis in host cells.

Definitions:

- The 30S and 50S ribosomes form the nucleosome complex that translates mRNA into protein.
- The 16S rRNA of the 30S ribosome is required for the initiation of protein synthesis and stabilization of correct codon-anticodon pairing in the A site of the ribosome during mRNA translation.
- The 23S rRNA of the 50S ribosome makes up the peptidyl transferase center, which catalyzes the polymerization of amino acids through peptide bonds.

Tetracyclines enter susceptible organisms by passive diffusion and by an energy-dependent transport protein mechanism unique to the bacterial inner membrane.

- Tetracyclines concentrate inside the bacterial cells and prevent protein synthesis by binding reversibly to the A site of the 30S ribosomal subunit, which prevents the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This prevents addition of amino acids to the growing peptide chain.
- Tetracyclines are effective against a broad spectrum of microorganisms – aerobic gram-positive and gram-negative bacteria, some anaerobes, spirochetes, atypical bacteria, rickettsia and protozoa.

Many strains of bacteria that cause common infections are now resistant.

- Mechanisms of resistance to tetracyclines are: 1) increased efflux or impaired influx, 2) ribosome protection by production of proteins that interfere with drug binding to the ribosome, and 3) enzymatic inactivation (less important than the first two mechanisms).
- Tet(AE) efflux pump expressed by gram-negative species confers resistance to tetracycline, doxycycline, and minocycline, but not to tigecycline and the other newer agents, which remain effective.
- Tet(K) efflux pump confers staphylococcal resistance to tetracycline, but not to doxycycline, minocycline, tigecycline and the other newer agents.
- Tet(M) ribosomal protection protein expressed by gram-positives confers resistance to tetracycline, doxycycline, and minocycline but not to the newer agents.
- *Pseudomonas aeruginosa* and *Proteus* spp are intrinsically resistant to all tetracyclines due to chromosomally-encodes MDR efflux pumps.

Key points

- Tetracyclines are absorbed adequately from the GI tract. Tetracycline's bioavailability is ~75-85% - some of the dose stays in the gut lumen and can alter the gut flora. Doxycycline and minocycline have nearly complete absorption. Administration with dairy products or other products containing divalent and trivalent cations form non-absorbable chelates, which decreases drug absorption, therefore, bioavailability. Doxycycline and minocycline are available in oral and intravenous forms. Tigecycline and eravacycline are IV only, omadacycline oral and IV, and sarecycline oral only.
- Tetracyclines bind plasma proteins to a moderate degree. They are widely distributed to body fluids and tissues, except CSF (concentrations 10-25% of plasma concentrations). They cross the placenta and are excreted in breast milk. Tetracyclines bind to calcium in growing long bones and teeth. Permanent tooth discoloration may occur, particularly with repeated or long-term exposure.
- Tetracyclines are excreted in urine and feces as unchanged drug and metabolites. Doxycycline and tigecycline are excreted mainly via the biliary system (nonrenal route) and do not accumulate in renal failure. Half-lives vary according to the individual drugs.

Key points

- The tetracyclines have similar efficacy. Doxycycline is the most frequently used agent in the class. It can be administered twice daily, given orally and IV, and achieves reasonable concentrations when given with food (but not with di-, trivalent cations).
- Doxycycline is the drug of choice for the treatment of Lyme disease (*Borrelia*, a spirochete) and Rocky Mountain spotted fever (*Rickettsia rickettsii*) and other zoonotic infections. Tetracyclines have excellent activity against the atypicals, *Mycoplasma pneumoniae* and *Chlamydia* spp. Doxycycline is used in combination with other antibacterial agents against zoonoses and *Helicobacter pylori* (peptic ulcer disease).
- Minocycline is an alternative for eradication of meningococcal carrier state (resistance increasing). Demeclocycline is not used as an antibiotic. It has been used in the treatment of syndrome of inappropriate antidiuretic hormone, due to its side effect (nephrogenic diabetes insipidus).
- Tigecycline, eravacycline, and omadacycline (oral) have a broad spectrum of activity, including against tetracycline-resistant strains. Sarecycline (oral) has a narrow spectrum: *Cutibacterium acnes* and other acne-causing gram-positive bacteria with little to no activity against gram-negative bacteria. It was specifically designed to treat acne.

Key points

- Most of the tetracyclines' adverse effects are due to direct toxicity or alteration of the microbiota. Hypersensitivity reactions (skin rashes, drug fever) are uncommon.
- GI discomfort due to direct local irritation – nausea, vomiting, diarrhea – are the most common adverse effects. Secondary infections, ie, *C. difficile* infection, due to alteration of the normal GI flora. Phototoxicity that can result in severe sunburn in sun-exposed skin. Impaired hepatic function is seen especially in pregnancy or patients with preexisting liver disease. Increased BUN/azotemia can occur in patients with renal impairment. Dizziness, vertigo, tinnitus, and benign increase intracranial pressure reported. Intravenous injection can cause venous thrombosis.

Drug-specific adverse effects:

- Minocycline – vestibular toxicity (reversible) and blue-gray or brown discoloration of skin and mucous membranes with long-term use.
- Demeclocycline – renal insensitivity to ADH (nephrogenic diabetes insipidus)
- Tigecycline – increase in all-cause mortality and acute pancreatitis
- Sarecycline is well tolerated with a low potential for adverse effects (nausea, vulvovaginal candidiasis).

Key points

Macrolides reversibly bind the 23S rRNA of the 50S subunit near the peptidyl transferase center, which blocks the polypeptide exit tunnel, and the unfinished peptide dissociates from the ribosome.

- Macrolides have excellent activity against streptococci and staphylococci (resistance is increasing), some gram-negative respiratory pathogens (resistance is increasing) and atypical bacteria, *Mycoplasma* (resistance is increasing), *Chlamydia* spp, and *Legionella*. They are generally bacteriostatic.
- Resistance mechanisms are: 1) ribosomal binding site modification by constitutive or inducible methylase production or chromosomal mutation expressing methylase (*erm* gene), 2) reduced permeability of the cell membrane or active efflux, 3) production of esterases by Enterobacteriales that hydrolyze the drugs. Methylase production and efflux are the most important mechanisms of resistance. Cross-resistance occurs between the macrolides. Cross-resistance due to methylation of the ribosomal binding site occurs between the macrolides, clindamycin, and streptogramin B, which is called MLS_B and is encoded by the *erm* gene.

- Erythromycin base is destroyed by stomach acid. Clarithromycin, azithromycin, and the salt forms of erythromycin are stable in stomach acid and well absorbed. Erythromycin and azithromycin are in oral and IV formulations; clarithromycin is oral. They are widely distributed in body fluids and tissues. The drugs concentrate in neutrophils and macrophages. They cross the placenta.
- Erythromycin and clarithromycin are substrates and strong inhibitors of CYP3A4. Azithromycin metabolism by CYP3A4 is minimal and it does not inhibit the drug metabolizing enzymes.
- Azithromycin is concentrated and excreted in the bile as active drug. Erythromycin is excreted in the bile as active drug and metabolites. Clarithromycin and its metabolites are excreted mainly in urine (dose adjustment in renal impairment).
- Azithromycin is sequestered in tissues and has a very long half-life (~70 hours).
- Azithromycin and clarithromycin are the most frequently prescribed macrolides.
- They are used in the treatment of respiratory infections, sexually transmitted infections, and other common infections. Macrolide resistance is increasing. NOTE: The CDC no longer recommends ceftriaxone-azithromycin dual therapy for uncomplicated gonorrhea as a strategy for preventing ceftriaxone resistance and possible *Chlamydia* coinfection. Erythromycin is used as a prokinetic agent (increase GI motility) by acting on motilin receptors in the gut. Topical uses include ocular infections and acne.

Key points

- All macrolides can increase the QT interval on EKG due to their effect on cardiac potassium channels, potentially resulting in ventricular fibrillation (torsades de pointes). Avoid in patients with proarrythmic conditions, and with other drugs that cause QT prolongation or increase macrolide levels.
- Nausea, vomiting, and diarrhea are common with erythromycin. Azithromycin and clarithromycin are better tolerated.

Clindamycin binds the 23S rRNA on the 50S ribosome near the peptidyl transferase center and interferes with transfer of amino acids to the growing peptide chain, interrupting protein synthesis.

- Clindamycin is used primarily in the treatment of streptococcal, staphylococcal (including MRSA) and anaerobic infections. It is bacteriostatic.
- Resistance mechanisms are, 1) modification of the receptor site by constitutively expressed methylase (MLS_B expressed by the *erm* gene) (see macrolides), 2) mutation of the ribosomal receptor site, and 3) enzymatic inactivation of clindamycin.
- Bacterial strains harboring inducible $iMLS_B$ methylase will appear susceptible to clindamycin. The D-zone test is recommended for infections caused by *Staphylococcus*, *S. pneumoniae*, and beta-hemolytic streptococci to determine if the $iMLS_B$ determinant is present. If present, constitutive production of methylase may be selected out, resulting in clindamycin therapy failure or recurrence of infection.

- Clindamycin is oral and IV, distributes well in body fluids but low concentrations in CSF. It penetrates well into abscesses, bones and joints, and is actively taken up into phagocytic cells. It is converted by CYP3A4 to inactive metabolites; it is not a CYP inhibitor or inducer. Small amounts of active drug and metabolites are excreted urine and feces. Dose adjustment for renal insufficiency is not necessary. It has a half-life of ~3 hours (2 to 4 divided doses per 24 hours).
- Clindamycin has been associated with severe *C. difficile* colitis (remember: all antibiotics can cause *C. difficile* infection). Diarrhea (non-*C. difficile*), nausea, and skin rashes are common. Impaired liver function and neutropenia sometimes occur. Pain / abscess with IM injection.

Chloramphenicol is a lipophilic broad-spectrum antibiotic restricted to treatment of life-threatening infections that have no alternatives because of its toxicities.

- It reversibly binds the 23S rRNA of the 50S ribosome in the peptidyl transferase, interferes with tRNA binding to peptidyl transferase, which prevents peptide bond formation between the incoming amino acid and the growing peptide chain. It is bacteriostatic.
- Resistance is due to plasmid-mediated acetyltransferase that covalently acetylates the drug. Efflux and ribosomal mutation have been described.
- The main uses are rickettsial infection (alternative to doxycycline), meningococcal meningitis (bacteriostatic), and typhoid fever
- Chloramphenicol also inhibits mitochondrial protein synthesis. Serious potential adverse effects include bone marrow toxicity, idiopathic aplastic anemia (low incidence, high fatality rate), gray syndrome affecting neonates and elderly, secondary infection, and GI adverse effects. It is a CYP2C9 inhibitor.

Key points

Chloramphenicol pharmacokinetics knowledge is important for optimal clinical outcomes:

- Chloramphenicol is administered IV. It is lipophilic and poorly soluble in water so is formulated as the succinate salt, which is rapidly hydrolyzed by esterases to active chloramphenicol. A portion of the salt form is rapidly cleared through the kidney before conversion to the active drug.
- It is moderately bound to plasma proteins. Free chloramphenicol is widely distributed in body fluids and tissues with high concentrations in CSF.
- Chloramphenicol is converted to inactive glucuronide metabolites.

Important – About babies:


- Neonates have immature metabolizing capacity and renal function.
- Immature UDP-glucuronyltransferase → reduced ability to metabolize chloramphenicol → potential for drug accumulation
- Reduced levels of plasma proteins → higher fraction of free drug
- Immature kidney function → ↑plasma concentrations of drug
- Increased drug concentration → increased risk of concentration-dependent toxicity:
Gray (baby) syndrome with lethargy, cyanosis, respiratory depression, cardiovascular collapse, and death.

Key points

Linezolid binds to a unique site on the 23S rRNA of the 50S subunit and perturbs the peptidyl transferase center, which affects tRNA positioning and binding to the A site, which inhibits the formation of the 70S initiation complex.

- Point mutations of the 23S rRNA genes encoding the binding site can lead to resistance (the most common resistance mechanism). Resistance among normally susceptible microorganisms remains relatively low. There is no cross-resistance with other drug classes.
- It is active against **gram-positive** MDR streptococci, staphylococci, enterococci, and gram-positive rods corynebacteria, *Listeria monocytogenes*, and *Nocardia*. Bactericidal against streptococci. Bacteriostatic against staphylococci and enterococci. Gram-negative and anaerobic organisms are intrinsically resistant.
- Linezolid is formulated for IV or oral administration, which has ~100% bioavailability. It is widely distributed in body fluids and tissues with high CSF concentrations. Metabolism is minimal (inactive metabolites). Excreted primarily in urine. Half-life is up to 3 hours; twice daily dosing.
- It is used in the treatment of MDR gram-positive infections.
- It is generally well tolerated. The main toxicities are thrombocytopenia, neutropenia, anemia, mitochondrial toxicities – peripheral neuropathies and lactic acidosis.
- Linezolid is a weak MAO inhibitor and is associated with serotonin syndrome in patients taking MAO inhibitors or serotonin reuptake inhibitors.

Classes of Common Protein Synthesis Inhibitors




Source: A.J. Trevor, B.G. Katzung, M. Kruidering-Hall: Katzung & Trevor's Pharmacology: Examination & Board Review, 11th Ed.
www.accesspharmacy.com
Copyright © McGraw-Hill Education. All rights reserved.

The following are not included in this lecture. If you are interested, the pharmacology of these drugs is described in the Notes Handout.

- The marketing of the streptogramins product, quinupristin/dalfopristin, has been discontinued.
- The pleuromutilin, lefamulin, binds the A- and P-sites of the peptidyl transferase, which prevents tRNA binding and peptide transfer for the treatment of community acquired pneumonia caused by *S. pneumoniae*, MSSA, *H. influenzae*, and *atypicals*.

From: 30 Protein Synthesis Inhibitors

Lippincott® Illustrated Reviews:
Pharmacology 8e, 2023



Legend:

Mechanisms of action of the various protein synthesis inhibitors.

Date of download: 8/22/2023

Copyright © Wolters Kluwer

Antibiotic Resistance

Intrinsic resistance: The microorganism has features that make it inherently resistant

Acquired resistance: Normally responsive organism acquires spontaneous, random chromosomal mutations, or transfer of resistance genes from other bacteria.

1. Drug does not reach target
2. Drug inactivation
3. Target alteration
4. Organism expresses alternative metabolic pathways

🔑 ***Frequent or long-term use of a particular drug increases the risk of microbial mutations that produce resistance to the drug.***

It is the responsibility of all health care professionals on a patient-to-patient basis to combat resistance by following stewardship guidelines and educating patients.

- **Tetracyclines**

Semisynthetic:



- * Tetracycline
- Oxytetracycline
- * Doxycycline
- * Minocycline
- * Demeclocycline

Synthetic:

- * Tigecycline (glycylcycline)
- Eravacycline (halogenated)
- Omadacycline
- Sarecycline

(The pharmacology of eravacycline, omadacycline, and sarecycline is described in the Pharmacology of the Protein Synthesis Inhibitors notes handout.)

PK-PD Profile: Data is limited
Bacteriostatic



glycylamido
group

Tetracyclines Class Pharmacokinetics Properties, in brief

<p>Oral, acid stable</p> <p>I.V.: Doxy- and Mino- Tigecycline (only I.V.)</p> <p>Bioavailability:</p> <p>Tetra- variable ~75-85%</p> <p>→ Doxy- 95% Mino- 100%</p> <p>Omadacycline ~35%</p>	<p>Protein binding 60-90%</p> <p>Widely distributed in body fluids</p> <p>Deposits in growing bones and tooth enamel.</p> <p>Doxycycline has low affinity for calcium.</p> <p>Avoid TCNs in pregnant women, children <8 years</p> <p>Exception: Doxycycline ≤21 days of treatment</p>	<p>All:</p> <p>Chelation in GI tract by: Di- and trivalent cations</p> <p>Avoid antacids and mineral supplements</p> <p>Food:</p> <p>TCN, demeclo-, omadacycline: Empty stomach</p> <p>Doxy-, Mino-, Sarecycline May be taken with food, including dairy products</p>
<p>TCN, Doxy-: not metabolized</p> <p>Mino-, Tig-: hepatic</p> <p>Excreted in urine, → except Doxy in feces</p> <p>t½ 9-16h, drug-specific Tigecycline ~40 h</p>	<p>Tetracyclines that remain in the gut lumen modify intestinal flora.</p>	




http://id3442.securedata.net/cosmetic-dentistry/tetracycline_stained_teeth.htm

Tetracycline-stained teeth

Doxycycline binds calcium less avidly and has not been shown to cause staining of permanent teeth.

The American Academy of Pediatrics now supports the use of doxycycline in young children if it is administered for ≤ 21 days since the risk is low when short courses are used.



Source: Bertram G. Katzung, Todd W. Vanderah:
Basic & Clinical Pharmacology, Fifteenth Edition
Copyright © McGraw-Hill Education. All rights reserved.

Tetracycline Mechanism of Action

(T) Tetracyclines bind to the acceptor site on the 30S ribosome and prevent the aminoacyl-tRNA from accessing the acceptor site on the mRNA-ribosome complex



Tetracyclines prevent addition of amino acids to the growing peptide chain.

Figure adapted by LG

Tetracyclines Mechanisms of Resistance

Active transport protein pump

Impaired influx or
Increased efflux

- Tet(K) efflux pump: *Staphylococcus* confers **resistance to tetracycline** but not to the others
- Tet(AE) efflux pump: Gram-negative bacteria confers **resistance to TCN, doxy- and mino-** but not to tigecycline, eravacycline, or omadacycline

Ribosomal protection proteins (RPPs)

Production of proteins that interfere with tetracycline binding to the ribosome

Enzymatic inactivation

Tet-type RPPs

Several classes expressed by gram-positive and gram-negative bacteria confer resistance

Tet(M): Streptococci, staphylococci, and enterococci resistance to tetracycline, doxycycline, and minocycline but not the newer agents.

Minor importance

Intrinsic resistance to all tetracyclines:

Proteus, P. aeruginosa intrinsic resistance by chromosomally encoded MDR efflux pumps

Mnemonics

TetK:

K almost looks like X – efflux

K sounds like C – Cocc (S. aureus is a G+ coccus)

Tet(AE): E=Efflux

A=aerobic; E=enteric
= Enterobacteriales

TetM:

M is in ribosoMe

Broad spectrum, Bacteriostatic; Activity against susceptible gram-positive and gram-negative aerobic and anaerobic bacteria.

Widespread resistance of bacteria causing common infections limits tetracyclines' clinical use.

Doxycycline is the most frequently used drug in the class.

Know the bugs and diseases in bold.

Infection	Disease examples	Pathogen
Zoonotic infections Doxycycline is a first-line agent. Frequently combined with fluoroquinolone or aminoglycoside.	Anthrax Ehrlichiosis Leptospirosis Lyme disease, Relapsing fever Plague Psittacosis Q fever Rocky Mountain spotted fever Tularemia “rabbit fever”	<i>Bacillus anthracis</i> <i>Ehrlichia spp</i> <i>Leptospira interrogans</i> <i>Borrelia spp</i> (spirochete) <i>Yersinia pestis</i> <i>Chlamydia psittaci</i> <i>Coxiella burnetti</i> <i>Rickettsia rickettsii</i> <i>Francisella tularensis</i>
Respiratory infections Doxycycline has good activity against respiratory pathogens	Community-acquired pneumonia Acute bacterial rhinosinusitis	<i>H. influenzae</i> <i>M. catarrhalis</i> <i>Mycoplasma pneumoniae</i> <i>C. pneumoniae</i>

Infection	Disease examples	Pathogen
Skin and skin structure infections	Acne vulgaris, severe (low dose)	<i>Propionibacterium</i>
Mild, localized infection	Various uncomplicated, community-acquired infections	MSSA MRSA
GI infections	Cholera Peptic ulcer disease 4-drug regimen	<i>Vibrio cholerae</i> <i>Helicobacter pylori</i>
Sexually transmitted diseases, serious Doxy- may be an choice for monotherapy or used in combination with other active drugs for severe infections	Pelvic inflammatory disease, Salpingitis Endometritis Peritonitis Lymphogranuloma venereum Nonspecific urethritis Syphilis, primary or secondary alternative to penicillin (x14-28 d)	<i>Chlamydia trachomatis</i> (obligate intracellular) <i>Treponema pallidum</i> (spirochete)
Malaria	Prophylaxis alternative (1x daily) Treatment with quinine	<i>Plasmodium</i> spp

Tigecycline

Therapeutic uses

Complicated skin and skin structure infections:

MRSA

vancomycin-sensitive *E. faecalis*

Complicated intra-abdominal infections:

Enterobacteriales

Gram-negative anaerobes
(excellent activity)

Community-acquired bacterial pneumonia:
Monotherapy *alternative* to both beta-lactams and fluoroquinolones due to association with increased mortality

Contraindicated uses

Do not use for the following infections:

Hospital-acquired pneumonia (HAP)

Healthcare-acquired pneumonia (HCAP)

Ventilator-associated pneumonia (VAP)

Tigecycline v. comparator antibiotic in clinical trials demonstrated:

- Lower efficacy,
- Lower cure rates, and
- Increased mortality.

Diabetic foot ulcers: Other agents are more effective.

DEMECLOCYCLINE

Not used for antibiotic properties.

Causes nephrogenic diabetes insipidus.

Historically used for SIADH treatment.

Tetracyclines / Tigecycline Adverse Effects

Secondary infections *C. difficile*; *Candida*

Modification of microbiota

Kidney

Increased blood urea nitrogen (BUN) / Azotemia
(caution in patients with ↓ renal function)

Fanconi syndrome with outdated TCN

Hepatotoxicity

Rare but can be fatal

Rare but serious

Increased intracranial pressure (young/old)

Thrombophlebitis (IV)

Neutropenia, Thrombocytopenia

GI

Nausea / vomiting / non-C. diff. diarrhea

Bones / Teeth (TCNs chelate calcium)

Deposit in bones/teeth of fetus, growing children
TCNs are **contraindicated** in pregnancy,
nursing infants, and children <8 years old.
Exception: Doxy now recommended ≤ 21 days

Skin

Photosensitivity, mild to severe

Hypersensitivity reactions

Reported (not common)

Rash, fever, hepatitis, pneumonitis, angioedema,
and anaphylaxis

Drug-specific Toxicities and Drug Interactions

Drug-specific Toxicities

Minocycline

vestibular toxicity

blue-gray or brownish discolorations of skin and mucous membranes with long-term use

Demeclocycline

nephrogenic diabetes insipidus

–insensitivity of the kidneys to vasopressin, also known as antidiuretic hormone–

Tigecycline

Increase in all-cause mortality when treating serious infections.

Acute pancreatitis

Drug Interactions

Decreased absorption

Antacids

Di-/trivalent cations in food and supplements

Bile acid binding resins

Warfarin: ↑ risk of bleeding due to injury to vitamin K producing bacteria in the gut

Oral contraceptives: ↓ enterohepatic circulation of estrogen → ↓ blood levels of the hormone → may reduce the efficacy of the hormone


Combined toxicity

Oral retinoids (acne medicine) and tetracyclines both can cause increased intracranial pressure.


The combination should be avoided.

Macrolides

- *Erythromycin
- *Clarithromycin
- *Azithromycin



E, C: 14-membered
ring structure
Lactone, 2 deoxy sugars



Azithromycin: 15-membered
ring structure
Lactone, 2 deoxy sugars

PK-PD Profile:
Erythromycin T>MIC
Clarithromycin and Azithromycin:
Clinical efficacy appears to be associated with AUC/MIC
Bacteriostatic

Macrolides Pharmacokinetics Key Points

Erythromycin: Oral variable absorption; I.V.

Azithromycin: Oral, I.V. } bioavailability: ~50%

Clarithromycin: Oral

Widely distributed in tissues

Accumulate in pulmonary tissue, middle ear fluid, and in phagocytic cells (PMNs and macrophages)

Hepatic metabolism

Erythromycin,
Clarithromycin:

- CYP3A4, P-gp substrates
- And strong CYP3A4, P-gp inhibitors

High potential for drug interactions

Azithromycin:

- Minimal CYP3A4 metabolism
- Not a CYP3A4 inhibitor
- Does inhibit P-gp

Excretion | $t_{1/2}$

Clarithromycin feces and urine, including active drug and active metabolite

- dose adjustment for renal impairment

Erythromycin, feces
Azithromycin, biliary

- No dose adjustment necessary for renal impairment

$t_{1/2}$ Erythromycin ~2 h
 $t_{1/2}$ Clarithromycin 3-9 h

$t_{1/2}$ Azithromycin ~70 h
1x daily dose
Tissue sequestration, prolonged antimicrobial effect


Proteins Synthesis Inhibitors: Macrolides Mechanisms of Action

(M) Macrolides bind the 50S ribosome at a site near the peptidyl transferase center.

Chain elongation (transpeptidation) is prevented by blocking the polypeptide exit tunnel within the enzyme.

(Some refer to macrolides as “tunnel plugs”.)

As a result, the unfinished peptide dissociates from the ribosome, interrupting protein synthesis.



Format of figure adapted by LG

Resistance Mechanisms

Intrinsic

Enterococci; Enterobacterales; *Pseudomonas*; *C. difficile*; *B. fragilis*
Reduced permeability to drug or production of drug modifying enzymes

Acquired: (main mechanisms)

Efflux

mrsA gene: staphylococci | *mefA* gene: GAS | *mefE* gene: *S. pneumoniae*
Plasmid encoded

Ribosomal modification

Methylase modifies the macrolide binding site → decreases drug binding
Constitutive, inducible or chromosomal mutation→ *erm* genes
(*erm*: erythromycin ribosomal methylase)

- Expressed by *S. pneumoniae*, *S. aureus*, *S. pyogenes*

CROSS-RESISTANCE Ribosomal modification → resistance to all macrolides

MLS_B: Macrolide-Lincosamide-Streptogramin B phenotype conferred by the *erm* gene

Resistance to macrolides, clindamycin, and streptogramin B, which all bind the same 23S target.

Azithromycin & Clarithromycin

are the most frequently used macrolide antibiotics.

Empiric
treatment of
respiratory
infections

Upper respiratory infections,
including in patients with COPD

M. catarrhalis, H. influenzae, S. pneumoniae

Community-acquired pneumonia

M. pneumoniae, C. pneumoniae, L. pneumophila

Whooping cough

Bordetella pertussis

Nontuberculosis mycobacterial

Mycobacterium avium-intracellulare (MAC)

STD

- Lymphogranuloma venereum
- Chancroid
- Gonorrhea

- *Chlamydia trachomatis*, alternative to doxy
- *H. ducreyi*, Azithromycin (or ceftriaxone)
- **Azithromycin is NO LONGER recommended for Gonorrhea / Chlamydia infection (with ceftriaxone)**

Skin / skin
structure

Widespread resistance

Macrolides should only be used if in vitro susceptibility has been documented.

GI

- Peptic ulcer disease
- Gastroenteritis

- *Helicobacter pylori*, Clarithromycin
- *Campylobacter jejuni*) Azithromycin

Zoonotic


Relapsing fever

Borrelia louse- or tick-borne, alternative to doxy

Macrolides Adverse Effects

- **GI:** Abdominal cramps, nausea, vomiting, and diarrhea
 - Erythromycin acts on motilin receptors | Azithro, Clarithro better tolerated
- **Cardiac:** QTc prolongation → ventricular arrhythmias
 - torsades de pointes (“twisting of the points”)
- **Hepatotoxicity:** esp. erythromycin estolate
 - Azithromycin-induced liver injury: Hepatitis; most patients recover but deaths have occurred
 - Hepatitis also reported with clarithromycin use.
- **Hypersensitivity:** immediate reactions reported; angioedema, urticaria, anaphylaxis
- **Pregnancy:** Azithromycin may be given.

Avoid clarithromycin and erythromycin estolate



Source: Knoop KJ, Stack LB, Storrow AB, Thurman RJ: *The Atlas of Emergency Medicine*, 3rd Edition: <http://www.accessmedicine.com>
Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

torsades de pointes


Macrolides Drug Interactions

Pharmacodynamics

- Drugs that act at/near 50S ribosomal subunit
- Drugs that prolong QT interval
- Warfarin (elimination of microbiome → ↓ vit K synthesis)

Pharmacokinetics: Erythromycin, Clarithromycin


- **Inhibition of CYP3A and P-glycoprotein** → ↑concentrations of many drugs, such as:
 - glucocorticoids; cyclosporine; **lovastatin, simvastatin, atrovastatin;** theophylline; triazolam; carbamazepine; valproate; ergot alkaloids
 - digoxin (probably by inhibition of P-gp)
- CYP3A4/P-gp inhibitors → ↑ risk of QT prolongation by azithromycin



*Clindamycin (a lincosamide)

PK-PD Profile: T>MIC

Bacteriostatic



Source: Brunton LL, Chabner BA, Knollmann BC: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 12th Edition: www.accessmedicine.com
Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Blocks transpeptidation by binding to the 23S of the 50S subunit near the peptidyl transferase center – the macrolides site

Clindamycin Properties

PK	Oral, IM, IV, topical; distributes to bone, abscesses, phagocytes, but low amounts in CSF even with inflamed meninges; CYP3A4 metabolism; active drug and metabolites excreted in urine/feces; $t_{1/2}$ 2-3 h
Activity	Gram-positive aerobes, caMRSA; G-positive and G-negative anaerobes Parasites: <i>Plasmodium</i> spp, <i>Toxoplasma gondii</i> , <i>Pneumocystis jiroveci</i>
Resistance	See next slide
Uses	Lung abscess, pelvic inflammatory disease, skin/skin structure infections, orofacial infections (dental use), acne (topical), bacterial vaginosis (vaginal), malaria, toxoplasmosis, <i>Pneumocystis</i> pneumonia
Adverse effects	<i>C. difficile</i> infection (dose-, time-related) → mild to severe (colitis, toxic megacolon), skin rashes (mild to severe), hepatic impairment reported
Pregnancy	Considered safe in pregnant patients.
Drug interactions	Other drugs that target 23S ribosome interfere with each other's actions, CYP3A4-mediated, oily base in vaginal cream may weaken condoms and contraceptive diaphragms

Clindamycin Resistance: MLS_B ribosomal methylation

- *Staphylococci* and *Streptococcus pneumoniae*: Inducible iMLS_B → may lead to cMLS_B during therapy: Bacterial strains will appear to be sensitive to clindamycin but clindamycin treatment in patients infected with organisms harboring cMLS_B (activated mRNA encoding methylase) may cause these mutants with constitutive production of methylase to be selected out and emerge during therapy → therapy failure or disease recurrence.

iMLS_B is prevalent in MRSA and *S. pneumoniae*.

The D test is recommended to determine if the iMLS_B determinant is present.


A positive D test suggests that a subpopulation of microbes resistant to clindamycin may emerge and lead to clinical failure or recrudescence.

A positive D test should be reported as resistant.

D Test

Panel A shows the isolate is resistant to erythromycin but has blunting of the zone of inhibition around the clindamycin disk (D zone), which is the hallmark of the inducible MLS_B resistance phenotype.

(Tracing around the D zone by LG)




Panels B,C, and D are described under the figure.

Commercially available erythromycin and clindamycin disks are placed in a standardized fashion on an agar plate inoculated with a standardized inoculum of the test organism. The plates are incubated for 16 to 24 hours and then visually inspected.


- (A) Flattening of the clindamycin zone of inhibition (D-zone) adjacent to the erythromycin disk, indicating inducible clindamycin resistance.
- (B) An isolate that is erythromycin-resistant but clindamycin-susceptible.
- (C) An isolate that is susceptible to both clindamycin and erythromycin.
- (D) An isolate with constitutive resistance to both clindamycin and erythromycin.

C: clindamycin disk; E: erythromycin disk.



*Chloramphenicol

Binds reversibly to 23S rRNA in 50S ribosome within peptidyl transferase center.
 Interferes with tRNA binding to the A site →
 Prevents the interaction between peptidyl transferase and the amino acid substrate →
 Prevents peptide bond formation



Source: Brunton LL, Chabner BA, Knollmann BC: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 12th Edition:
www.accessmedicine.com
 Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Chloramphenicol is highly lipophilic and poorly soluble in water.
 It is formulated as water soluble inactive succinate sodium salt for I.V. administration.

Chloramphenicol Properties

PK	IV, succinate salt is rapidly converted by esterases to active chloramphenicol protein binding ~60% widely distributed with good penetration of CSF, ocular tissues, prostate glucuronide conjugation, inactive metabolites; urine, $t_{1/2} \sim 4$ h
Activity	Broad-spectrum, bacteriostatic (<i>P. aeruginosa</i> is intrinsically resistant.)
Resistance	Drug inactivation by covalent acetylation by bacterial acetyltransferase
Uses	Limited: restricted to life-threatening infections when no alternative can be used Rocky Mountain spotted fever (<i>R. rickettsii</i>), enteric (typhoid) fever meningococcal meningitis (bacteriostatic)
Adverse effects	Mitochondrial toxicity – due to inhibition of mitochondrial protein synthesis Bone marrow toxicity, idiopathic aplastic anemia, Gray syndrome (next slide) GI: nausea, vomiting, diarrhea, stomatitis, glossitis optic neuritis, peripheral neuritis, headache, confusion
Pregnancy	Recommended <i>alternative</i> for treatment of Rocky Mountain spotted fever and plague (<i>Y. pestis</i>) Caution in 3 rd trimester (concern about gray baby syndrome)
DDIs	CYP2C9 inhibitor; other drugs with same adverse effects

Chloramphenicol is a high-risk medication in pediatric patients.

Neonates (premature and full-term newborns and infants) have immature hepatic and renal functions.

1. Immature UDP-glucuronyltransferase (UGT) → reduced ability to metabolize chloramphenicol → potential for drug accumulation
2. Reduced levels of plasma proteins → higher fraction of free drug
3. Immature kidney function → ↑plasma concentrations of drug
Increased drug concentration → increased risk of concentration-dependent toxicity.

Gray (baby) syndrome


- Drug accumulation in neonate → toxic levels
- Vomiting, flaccid muscles, abdominal distension, hypothermia, gray color (cyanosis)
- Vasomotor collapse, irregular respirations, death

Onset: 2-9 days after starting therapy

Progression of symptoms is rapid. Prompt termination of therapy is required.

 Monitor serum chloramphenicol concentrations in neonates, infants, children, and patients with impaired hepatic function.

Oxazolidinone moiety




Linezolid

Oxazolidinones

*Linezolid

- Tedizolid

1. Bind the 23S rRNA in the 50S subunit in the A site pocket near the interface with the 30S subunit
2. Prevent the formation of the ribosomal-fMet-tRNA complex that initiates protein synthesis
3. Inhibit formation of the first peptide bond of the nascent peptide



Linezolid Properties

PK	IV and oral, 100% bioavailability; widely distributed including lung tissue, bone, and CSF (high concentrations); hepatic but minimal metabolism, inactive metabolites; nonrenal and renal excretion; $t_{1/2} \sim 5$ h adults, 1.5-3 h children
Activity gram-positive	Bactericidal against streptococci Bacteriostatic against staphylococci, including MRSA, and enterococci, including VRE <i>Mycobacterium tuberculosis</i> (MDR and XDR strains)
Resistance	Low level resistance, no cross-resistance Mechanism: Point mutations in the binding site on the 23S ribosomal rRNA gene confer resistance in staphylococci and enterococci
Intrinsic	Resistance: Aerobic gram-negative bacteria and anaerobic bacteria
Uses	Skin/skin structure; nosocomial and ca-pneumonia, CNS infections, bone and joint infections, drug-resistant tuberculosis, and more
Adverse effects	Thrombocytopenia (Tx duration >2 weeks); Mitochondrial toxicities – peripheral neuropathy, optic neuritis, lactic acidosis (reported with Tx duration ≥ 28 days)
DDIs	Next slide

Linezolid Adverse Effects

Linezolid is a weak monoamine oxidase (MAO) inhibitor



increases levels of serotonin and norepinephrine in the brain and periphery



increases the risk of serotonin syndrome in patients taking serotonergic drugs

Serotonin syndrome typically is reversible and ranges from mild to a potentially life-threatening event resulting from drug combinations that increase serotonin levels in the brain:

headache, confusion, palpitations, hyperreflexia, hyperthermia, hypertensive crisis

Pregnancy: Limited data

Drugs-disease interactions:

- Uncontrolled hypertension
- Pheochromocytoma
- Thyrotoxicosis

Drug-drug interactions

Avoid concomitant use with:

- Serotonin reuptake inhibitors
- Tricyclic antidepressants
- Meperidine
- Sympathomimetic agents
- Vasopressive agents

Drugs-food interactions:

- Dietary tyramine

Tyramine is deactivated by intestinal and hepatic MAO.

Questions: You might want to pause the video to think about them.

1. Which drug classes fit the following mechanisms of action?
 - A. Bind the 30S subunit of the bacterial ribosome, preventing binding of tRNA to the mRNA–ribosome complex.
 - B. Bind the 30S ribosomal subunit, interfering with assembly of the functional ribosomal apparatus and cause misreading of the code.
 - C. Bind the bacterial 23S ribosomal RNA of the 50S subunit, inhibiting the formation of the 70S initiation complex.
 - D. Bind to a site on the 50S subunit of the bacterial ribosome, inhibiting translocation steps of protein synthesis (“tunnel plug”).
 - E. Bind to a site on the 50S subunit of the bacterial ribosome, inhibiting the interaction between the amino acid and peptidyl transferase
2. Why does the American Academy of Pediatrics support the use of doxycycline for up to 21 days in young children?
3. What is the mechanism by which chloramphenicol may cause vomiting, flaccid muscles, hypothermia, cyanosis, vasomotor collapse, irregular respirations, and death in the newborn?

Questions continue.

4. Which drug is the preferred treatment for many zoonotic infections, including Rocky Mountain spotted fever?
5. What are the three toxicities associated with the class of drugs that utilize the microbe's oxygen transport system to gain access to the protein synthesis apparatus?
6. What is the current CDC recommendation regarding treatment of gonorrhea and potential chlamydia coinfection with azithromycin?
7. What drug is safe and effective in all trimesters for the outpatient treatment of community acquired pneumonia (CAP) for a generally healthy pregnant patient?
8. A patient with a diabetic foot infection caused by methicillin-resistant *S. aureus* identified by culture and sensitivity testing requires treatment. The patient is taking citalopram for depression (a selective serotonin reuptake inhibitor). What drug would be effective but contraindicated?
9. A 70-year-old patient is diagnosed with community acquired pneumonia. The patient takes sotalol (antiarrhythmic) for management of atrial flutter. What class of drugs may increase the risk of torsades de pointes in this patient?
10. What protein synthesis inhibitors do not require dose adjustments for renal insufficiency because they are not excreted as active drug in urine? mnemonic **Dear Aunt Catherine's Quilt**⁴⁸


Summary of Protein Synthesis Inhibitors

Synopsis

- Protein synthesis inhibitors have diverse chemical structures, pharmacokinetic properties, actions, and antibacterial spectrums.
- The protein synthesis inhibitors subclasses vary in their sites of action on the bacterial ribosome to inhibit addition of amino acids to the growing peptide chain.
- Protein synthesis inhibitors, as a group, are predominantly bacteriostatic against a wide array of bacteria, including intracellular organisms and those lacking a cell wall. Most have activity against susceptible ca-MRSA. The macrolides are not.
- Resistance is increasing. Efflux or reduced influx and alteration of the ribosomal target are common mechanisms. Drug inactivation is less common but important for chloramphenicol resistance.
- Toxicity potential ranges from negligible to severe.

Bacterial protein synthesis inhibitors

Summary of Spectrums of Activity, if bacterial resistance is absent



1. A. tetracyclines B. aminoglycosides C. linezolid (oxazolinones) D. macrolides E. chloramphenicol
2. Doxycycline does not bind calcium as avidly as tetracycline does and the risk of tooth discoloration is low when used for ≤ 21 days.
3. Elevated serum chloramphenicol levels due to immature UGT and renal function and lower albumin levels (greater free drug fraction) significantly prolongs half-life and increases risk of mitochondrial toxicity → cyanosis and Gray Syndrome.
4. Doxycycline and for several other zoonoses. (Tularemia is treated with an AG, streptomycin or gentamicin.)
5. Aminoglycosides' toxicities are nephrotoxicity, ototoxicity, and neuromuscular blockade / respiratory failure.
6. Azithromycin is not recommended because of increasing gonococcal resistance. If there is a high suspicion of chlamydia coinfection, doxycycline is recommended.
7. Azithromycin may be given in pregnancy. AVOID clarithromycin, erythromycin estolate, tetracyclines, fluoroquinolones, chloramphenicol, lefamulin. (Linezolid and clindamycin would not be effective against all potential pneumonia-causing bacteria.)
8. Linezolid is a weak MAO inhibitor and should be avoided in patients taking drugs that increase synaptic serotonin levels. Serotonin syndrome. Linezolid is an alternative for patients who do not respond to other agents (cost/toxicity).
9. Macrolides and antiarrhythmics that block cardiac potassium channels both cause prolongation of the QT interval. The risk of ventricular arrhythmia is increased when used together.
10. Dear Aunt Catherine's Quilt – Doxycycline, Azithromycin, Clindamycin, and Quinupristin-dalfopristin do not require dose adjustment in patients with renal insufficiency.

References

- Access Medicine Goodman & Gilman's The Pharmacological Basis of Therapeutics 14e, 2023; Chapter 60: Protein Synthesis Inhibitors
- Access Medicine Harrison's Principles of Internal Medicine, 20e, 2018; Chapter 163: Cholera and Other Vibrioses
- Access Medicine Jawetz, Melnick, & Adelberg's Medical Microbiology, 27e, 2016; Chapter 14: The Streptococci, Enterococci, and Related Genera; Chapter 15: Enteric Gram-Negative Rods (enterobacteriaceae)
- Access Medicine Katzung's Basic & Clinical Pharmacology 16e, 2024; Chapter 44: Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, Oxazolidinones & Pleuromutilins
- Lexidrugs monographs
- The Sanford Guide to Antimicrobial Therapy, 55e, 2025

Lecture Feedback Form:

<https://comresearchdata.nyit.edu/redcap/surveys/?s=HRCY448FWYXREL4R>